Perbak Capital Partners LLP Takes Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Perbak Capital Partners LLP purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,799 shares of the medical research company's stock, valued at approximately $1,456,000.

Several other hedge funds have also modified their holdings of the stock. Norges Bank acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $3,149,754,000. T. Rowe Price Investment Management Inc. grew its position in shares of Thermo Fisher Scientific by 86.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock worth $1,604,338,000 after buying an additional 1,433,444 shares during the period. Kovitz Investment Group Partners LLC increased its stake in shares of Thermo Fisher Scientific by 1,905.4% in the 4th quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company's stock valued at $469,889,000 after acquiring an additional 858,193 shares during the last quarter. Proficio Capital Partners LLC boosted its stake in Thermo Fisher Scientific by 68,617.0% during the 4th quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company's stock worth $396,810,000 after acquiring an additional 761,649 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $377,901,000. 89.23% of the stock is owned by institutional investors.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares of the company's stock, valued at $59,506,950.58. This represents a 7.99 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Stephen Williamson sold 9,825 shares of the business's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. This represents a 26.47 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 24,200 shares of company stock worth $13,235,041. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO traded up $3.80 on Friday, hitting $423.69. The company's stock had a trading volume of 2,492,422 shares, compared to its average volume of 1,769,242. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a one year low of $409.85 and a one year high of $627.88. The stock has a fifty day moving average of $478.47 and a two-hundred day moving average of $522.86. The firm has a market capitalization of $159.94 billion, a P/E ratio of 25.63, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company's quarterly revenue was up .2% on a year-over-year basis. During the same period in the previous year, the company earned $5.11 earnings per share. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date was Friday, March 14th. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on TMO shares. UBS Group decreased their price target on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a report on Thursday, April 24th. Scotiabank dropped their price target on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a research report on Friday, April 25th. Stifel Nicolaus lowered their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price target on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a research note on Wednesday, April 23rd. Finally, Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price objective on the stock in a report on Friday, January 10th. Five equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and an average target price of $607.43.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.